Townsquare Capital LLC Acquires 13,210 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Townsquare Capital LLC raised its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 38.0% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 47,953 shares of the medical instruments supplier's stock after acquiring an additional 13,210 shares during the period. Townsquare Capital LLC owned about 0.21% of LeMaitre Vascular worth $4,454,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of LMAT. Conestoga Capital Advisors LLC boosted its holdings in LeMaitre Vascular by 1.9% during the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier's stock worth $183,769,000 after purchasing an additional 36,850 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of LeMaitre Vascular by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier's stock valued at $103,112,000 after acquiring an additional 4,964 shares in the last quarter. Copeland Capital Management LLC grew its holdings in shares of LeMaitre Vascular by 1.0% in the 3rd quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier's stock valued at $108,068,000 after acquiring an additional 11,318 shares in the last quarter. Congress Asset Management Co. raised its holdings in LeMaitre Vascular by 2.6% during the third quarter. Congress Asset Management Co. now owns 709,316 shares of the medical instruments supplier's stock worth $65,888,000 after acquiring an additional 18,295 shares in the last quarter. Finally, Driehaus Capital Management LLC raised its holdings in LeMaitre Vascular by 52.2% during the second quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier's stock worth $21,740,000 after acquiring an additional 90,573 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company's stock.

Insiders Place Their Bets

In other news, Director Bridget A. Ross sold 3,750 shares of the company's stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares of the company's stock, valued at approximately $231,148.66. This represents a 62.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 10.79% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on LMAT shares. StockNews.com lowered LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. JMP Securities upped their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a "market outperform" rating in a research report on Tuesday, August 20th. Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They issued a "buy" rating and a $105.00 price objective for the company. Barrington Research raised their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an "outperform" rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald assumed coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They set a "neutral" rating and a $96.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $94.57.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT traded up $1.19 during trading hours on Friday, reaching $106.99. 59,820 shares of the stock were exchanged, compared to its average volume of 123,959. The stock's fifty day simple moving average is $95.18 and its 200 day simple moving average is $87.68. LeMaitre Vascular, Inc. has a 52 week low of $51.70 and a 52 week high of $109.58. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of 58.46, a P/E/G ratio of 2.59 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. LeMaitre Vascular's revenue was up 15.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.33 earnings per share. Research analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.60%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular's dividend payout ratio is currently 34.97%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.